

# Uganda

Population 2016

41 million

| Estimates of TB burden*, 2016 | Number (thousands) | Rate (per 100 000 population) |
|-------------------------------|--------------------|-------------------------------|
| Mortality (excludes HIV+TB)   | 11 (5.8–17)        | 26 (14–41)                    |
| Mortality (HIV+TB only)       | 14 (8.3–22)        | 35 (20–53)                    |
| Incidence (includes HIV+TB)   | 83 (49–127)        | 201 (118–306)                 |
| Incidence (HIV+TB only)       | 35 (20–54)         | 85 (49–131)                   |
| Incidence (MDR/RR-TB)**       | 1.9 (0.98–2.9)     | 4.7 (2.4–7)                   |

| Estimated TB incidence by age and sex (thousands)*, 2016 | 0-14 years    |             | > 14 years  |      | Total |
|--|---------------|-------------|-------------|------|-------|
|  | Number        | Rate        | Number      | Rate |       |
| Females  | 4 (2.2–5.9)   | 19 (10–28)  | 23 (12–33)  |      |       |
| Males  | 4.6 (2.5–6.8) | 56 (30–82)  | 61 (32–89)  |      |       |
| Total  | 8.7 (4.6–13)  | 75 (40–110) | 83 (49–127) |      |       |

| TB case notifications, 2016                            |        |
|--|--------|
| Total cases notified                                   | 44 816 |
| Total new and relapse                                  | 43 413 |
| - % tested with rapid diagnostics at time of diagnosis | 24%    |
| - % with known HIV status                              | 94%    |
| - % pulmonary  | 92%    |
| - % bacteriologically confirmed among pulmonary        | 68%    |

| Universal health coverage and social protection                        |                  |
|--|------------------|
| TB treatment coverage (notified/estimated incidence), 2016             | 52% (34–88)      |
| TB patients facing catastrophic total costs                            |                  |
| TB case fatality ratio (estimated mortality/estimated incidence), 2016 | 0.32 (0.16–0.51) |

| TB/HIV care in new and relapse TB patients, 2016    | Number | (%) |
|---|--------|-----|
| Patients with known HIV-status who are HIV-positive | 18 225 | 43% |
| - on antiretroviral therapy                         | 16 403 | 90% |

| Drug-resistant TB care, 2016                                | New cases       | Previously treated cases  | Total number***   |
|---|-----------------|---------------------------|-------------------|
| Estimated MDR/RR-TB cases among notified pulmonary TB cases |                 |                           | 1 000 (590–1 400) |
| Estimated % of TB cases with MDR/RR-TB                      | 1.6% (0.78–2.4) | 12% (3.4–21)              |                   |
| % notified tested for rifampicin resistance                 | 15%             | 50%                       | 12 065            |
| MDR/RR-TB cases tested for resistance to second-line drugs  |                 |                           | 101               |
| Laboratory-confirmed cases                                  |                 | MDR/RR-TB: 489, XDR-TB: 4 |                   |
| Patients started on treatment ****                          |                 | MDR/RR-TB: 374, XDR-TB: 4 |                   |

| Treatment success rate and cohort size                          | Success | Cohort |
|---|---------|--------|
| New and relapse cases registered in 2015                        | 75%     | 41 516 |
| Previously treated cases, excluding relapse, registered in 2015 | 67%     | 2 114  |
| HIV-positive TB cases registered in 2015                        | 75%     | 16 948 |
| MDR/RR-TB cases started on second-line treatment in 2014        | 71%     | 214    |
| XDR-TB cases started on second-line treatment in 2014           |         | 0      |

| TB preventive treatment, 2016   |                |
|---|----------------|
| % of HIV-positive people (newly enrolled in care) on preventive treatment                                   |                |
| % of children (aged < 5) household contacts of bacteriologically-confirmed TB cases on preventive treatment | 5.2% (4.8–5.7) |

| TB financing, 2017   |    |
|--|----|
| National TB budget (US\$ millions)                           | 54 |
| Funding source: 3% domestic, 26% international, 71% unfunded |    |

\* Ranges represent uncertainty intervals


\*\* MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin

\*\*\* Includes cases with unknown previous TB treatment history

\*\*\*\* Includes patients diagnosed before 2016 and patients who were not laboratory-confirmed


## Tuberculosis profile

(Rate per 100 000 population per year)




— Mortality (excludes HIV+TB)

(Rate per 100 000 population per year)



— Incidence  
— Notified (new and relapse)  
— Incidence (HIV+TB only)

Notified cases by age group and sex, 2016



Treatment success rate (%)



— New and relapse  
— Retreatment, excluding relapse  
— HIV-positive — MDR/RR-TB — XDR-TB

Total budget (US\$ millions)

